Innovative ¿armed¿ antibodies

• Unité de recherche: INNOSUISSE
• Numéro de projet: 12803.1;11 VOUCH-LS
• Titre du projet anglais: Innovative ¿armed¿ antibodies

Description succincte (Allemand)

Innovative 'armed' antibodies

Description succincte (Anglais)

Innovative ¿armed¿ antibodies

Résumé des résultats (Abstract) (Allemand)

Monoclonal antibodies represent the largest and fastest growing class of biotechnology products. While conventional antibody products are based on intact IgG, there is a growing trend towards ¿arming¿ antibodies with therapeutic payloads. The Philogen group is one of the pioneers in the engineering of armed human antibodies for therapeutic applications. In order to retain and consolidate its leadership in the field, we need to stay ahead of competition and explore innovative immunocytokines, alongside with their possible clinical application areas.

Résumé des résultats (Abstract) (Anglais)

Monoclonal antibodies represent the largest and fastest growing class of biotechnology products. While conventional antibody products are based on intact IgG, there is a growing trend towards ¿arming¿ antibodies with therapeutic payloads. The Philogen group is one of the pioneers in the engineering of armed human antibodies for therapeutic applications. In order to retain and consolidate its leadership in the field, we need to stay ahead of competition and explore innovative immunocytokines, alongside with their possible clinical application areas.